NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Sunday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets dropped their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NBY stock opened at $0.71 on Friday. The stock has a market cap of $3.49 million, a PE ratio of -0.01 and a beta of 0.65. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $9.08. The firm has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.80.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.